VCYT - Veracyte Inc Stock Price, Fair Value and News

$45.48-0.66 (-1.43%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

VCYT Price Action

Last 7 days

3.8%


Last 30 days

14.9%


Last 90 days

32.6%


Trailing 12 Months

79.3%

VCYT RSI Chart

MayJunJulAugSepOctNovDec202520304050607080

VCYT Valuation

Market Cap

3.5B

Price/Earnings (Trailing)

-380.31

Price/Sales (Trailing)

8.29

EV/EBITDA

211.48

Price/Free Cashflow

62.4

VCYT Price/Sales (Trailing)

2022202320242025510152025

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

425.3M

Rev. Growth (Yr)

28.58%

Rev. Growth (Qtr)

1.25%

20122014201620182020202220240100M200M300M400M

VCYT Earnings

Earnings (TTM)

-9.3M

Earnings Growth (Yr)

151.17%

Earnings Growth (Qtr)

164.3%

2012201420162018202020222024-80M-60M-40M-20M0

VCYT Profitability

Operating Margin

91.52%

EBT Margin

-1.92%

Return on Equity

-0.79%

Return on Assets

-0.73%

Free Cashflow Yield

1.6%

VCYT Investor Care

Shares Dilution (1Y)

6.11%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2012201420162018202020222024050M100M150M200M250M300M350M400M450M
Net sales
YearQ1Q2Q3Q4
2024375.5M399.6M425.3M0
2023311.2M328.6M343.1M361.1M
2022250.6M268.4M283.6M296.5M
2021123.1M157.5M186.7M219.5M
2020122.0M112.5M112.7M117.5M
2019101.5M108.9M116.4M120.4M
201875.6M79.9M85.9M92.0M
201768.0M71.7M70.6M72.0M
201651.8M54.6M60.9M65.1M
201541.9M45.2M47.7M49.5M
201425.0M28.6M32.8M38.2M
201314.5M17.1M19.5M21.9M
20124.9M7.1M9.4M11.6M
20110002.6M
Get all data in R, Python etc through our Historical Stock Data APIs
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEveracyte.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES787

Veracyte Inc Frequently Asked Questions


What is the ticker symbol for Veracyte Inc? What does VCYT stand for in stocks?

VCYT is the stock ticker symbol of Veracyte Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Veracyte Inc (VCYT)?

As of Fri Jan 31 2025, market cap of Veracyte Inc is 3.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VCYT stock?

You can check VCYT's fair value in chart for subscribers.

Is Veracyte Inc a good stock to buy?

The fair value guage provides a quick view whether VCYT is over valued or under valued. Whether Veracyte Inc is cheap or expensive depends on the assumptions which impact Veracyte Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VCYT.

What is Veracyte Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jan 31 2025, VCYT's PE ratio (Price to Earnings) is -380.31 and Price to Sales (PS) ratio is 8.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VCYT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Veracyte Inc's stock?

In the past 10 years, Veracyte Inc has provided 0.188 (multiply by 100 for percentage) rate of return.